Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.50 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 2/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.46 |
| ▸ | RXRA | P19793 | 2/20 | 0.45 |
| ▸ | RXRB | P28702 | 2/20 | 0.45 |
| ▸ | RXRG | P48443 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | CSF1R | P07333 | 2/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
| ▸ | CHKA | P35790 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16655520 | 0.85 | RXRA (0.40) | KDRFGFR1EPHB4KITPDGFRA | |
| SCHEMBL1024535 | 0.85 | KDR (0.39) | KDRFGFR1EPHB4GRM4KIT | |
| SCHEMBL5394102 | 0.83 | CHKA (0.44) | KDRFGFR1EPHB4RXRARXRB | |
| SCHEMBL20612458 | 0.79 | KDR (0.36) | KDRFGFR1EPHB4GRM4KIT | |
| SCHEMBL17261126 | 0.79 | ABCG2 (0.47) | EGFRMAPT | |
| SCHEMBL13535553 | 0.78 | KDR (0.38) | KDRFGFR1EPHB4KITPDGFRA | |
| SCHEMBL6313916 | 0.78 | IGF1R (0.54) | KDRKITPDGFRADOT1L | |
| SCHEMBL13670044 | 0.77 | APP (0.47) | KDRFGFR1EPHB4KITPDGFRA | |
| SCHEMBL25453063 | 0.77 | EGFR (0.46) | KDRFGFR1EPHB4GRM4KIT | |
| SCHEMBL30502771 | 0.77 | EGFR (0.46) | KDRFGFR1EPHB4GRM4KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101668749-A | Novel pyrimidine derivatives 698 | ASTRAZENECA AB | 2010-03-10 | — | — | CN | disclosed |
| EP-2132184-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | AstraZeneca AB (SE) | 2009-12-16 | — | — | EP | disclosed |
| US-20080242663-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | US | disclosed |
| US-20080242663-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | US | disclosed |
| US-20080242663-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | US | disclosed |
| WO-2008104754-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242663-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | EPHB4, EPHB1, NME2 | KDR 1003/4885FGFR1 661/4885EPHB4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.